Beam Therapeutics Q3 Earnings Forecast Cut by HC Wainwright

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Beam Therapeutics to a loss of $1.26 per share from $1.25, while maintaining a “Buy” rating. The firm projects a $4.67-per-share loss for full-year 2026.
• Beam shares were up 15.6%, opening at $28.78, amid positive early Phase 1/2 data for its BEAM-301 gene-editing therapy. Two patients showed improved glucose control and no longer needed starch supplementation.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and average price target of $46.40, although Wedbush recently cut its target sharply from $65 to $28. Institutional investors own 99.68% of the stock.

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Beam Therapeutics in a research note issued on Tuesday, October 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($1.26) for the quarter, down from their prior forecast of ($1.25). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.49) per share. HC Wainwright also issued estimates for Beam Therapeutics' Q4 2026 earnings at ($1.32) EPS, FY2026 earnings at ($4.67) EPS, Q1 2027 earnings at ($1.28) EPS, Q2 2027 earnings at ($1.30) EPS, Q3 2027 earnings at ($1.25) EPS, Q4 2027 earnings at ($1.30) EPS, FY2027 earnings at ($5.23) EPS, FY2028 earnings at ($4.39) EPS, FY2029 earnings at ($3.04) EPS and FY2030 earnings at ($1.48) EPS.

BEAM has been the topic of several other research reports. William Blair upgraded Beam Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 23rd. Bank of America restated a "buy" rating and set a $47.00 price objective on shares of Beam Therapeutics in a research note on Wednesday, July 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Beam Therapeutics in a research report on Thursday, October 15th. Wall Street Zen raised Beam Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, October 3rd. Finally, Wedbush cut their target price on Beam Therapeutics from $65.00 to $28.00 and set an "outperform" rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $46.40.

Beam Therapeutics Stock Up 15.6%

Shares of Beam Therapeutics stock opened at $28.78 on Thursday. The company has a current ratio of 14.57, a quick ratio of 14.57 and a debt-to-equity ratio of 0.09. The business's 50 day simple moving average is $25.96 and its 200-day simple moving average is $28.21. The stock has a market capitalization of $2.97 billion, a price-to-earnings ratio of -33.46 and a beta of 2.20. Beam Therapeutics has a twelve month low of $20.23 and a twelve month high of $38.26.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($1.18) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.07). The company had revenue of $0.49 million during the quarter, compared to analyst estimates of $16.37 million. Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. The business's revenue was down 94.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.00) earnings per share.

Hedge Funds Weigh In On Beam Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SBI Securities Co. Ltd. increased its holdings in shares of Beam Therapeutics by 15.6% during the third quarter. SBI Securities Co. Ltd. now owns 4,572 shares of the company's stock valued at $112,000 after purchasing an additional 618 shares during the period. Versant Capital Management Inc raised its stake in shares of Beam Therapeutics by 123.6% during the third quarter. Versant Capital Management Inc now owns 1,239 shares of the company's stock valued at $30,000 after purchasing an additional 685 shares in the last quarter. Swiss National Bank lifted its holdings in Beam Therapeutics by 0.6% in the first quarter. Swiss National Bank now owns 180,600 shares of the company's stock worth $4,304,000 after purchasing an additional 1,100 shares during the period. Royal Bank of Canada lifted its holdings in Beam Therapeutics by 7.3% in the first quarter. Royal Bank of Canada now owns 16,825 shares of the company's stock worth $401,000 after purchasing an additional 1,144 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in Beam Therapeutics by 1,372.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,252 shares of the company's stock worth $43,000 after purchasing an additional 1,167 shares during the period. 99.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Beam Therapeutics

In other Beam Therapeutics news, CEO John Evans sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $23.57, for a total value of $589,250.00. Following the sale, the chief executive officer owned 1,047,205 shares in the company, valued at approximately $24,682,621.85. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.80% of the company's stock.

Key Stories Impacting Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Initial Phase 1/2 data provided proof of concept for BEAM-301: two patients in the 40 mg cohort achieved 15 hours of controlled fasting, showed improved glucose control and no longer required starch supplementation. The reported safety profile was consistent with other lipid-nanoparticle therapies. Beam Therapeutics BEAM-301 clinical data
• Positive Sentiment: Beam plans to discuss a potential regulatory path with the FDA, while enrollment in the 60 mg cohort is underway. A successful one-time treatment could represent a significant commercial opportunity in the rare-disease market. MarketScreener BEAM-301 clinical data
• Positive Sentiment: H.C. Wainwright reportedly viewed the early BEAM-301 results as supporting substantial additional upside, helping reinforce bullish sentiment around Beam’s gene-editing platform. Stocktwits report on BEAM-301 and H.C. Wainwright outlook
• Negative Sentiment: Wedbush cut its price target for BEAM sharply from $65 to $28, citing a much lower valuation ceiling despite maintaining an “Outperform” rating. The new target suggests limited near-term upside based on the quoted share price. Wedbush lowers Beam Therapeutics price target

Beam Therapeutics Company Profile

Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company's platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.

Beam's pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.